SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

21 Oct 2022 Evaluate
The sales moved up 47.73% to Rs. 2229.70 millions for the September 2022 quarter as compared to Rs. 1509.30 millions during the year-ago period.A humble growth in net profit of 6.27% reported in the quarter ended September 2022 to Rs. 918.10  millions from Rs. 863.90 millions.Operating Profit saw a handsome growth to 1134.20 millions from 1035.40 millions in the quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 2229.70 1509.30 47.73 4275.40 3295.70 29.73 877.50 27095.00 -96.76
Other Income 1061.20 1061.20 0.00 1163.60 1104.00 5.40 1258.70 478.80 162.89
PBIDT 1134.20 1035.40 9.54 1192.90 1143.80 4.29 1190.90 4749.40 -74.93
Interest 41.40 26.60 55.64 72.90 53.30 36.77 305.90 1018.00 -69.95
PBDT 1092.80 1008.80 8.33 1120.00 1090.50 2.71 885.00 3731.40 -76.28
Depreciation 110.80 92.60 19.65 202.90 184.20 10.15 62.50 999.70 -93.75
PBT 982.00 916.20 7.18 917.10 906.30 1.19 822.50 2731.70 -69.89
TAX 63.90 52.30 22.18 50.80 50.00 1.60 37.50 586.90 -93.61
Deferred Tax -80.10 -108.20 -25.97 -93.20 -111.40 -16.34 -99.10 132.50 -174.79
PAT 918.10 863.90 6.27 866.30 856.30 1.17 785.00 2144.80 -63.40
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 50.87 68.60 -25.85 27.90 34.71 -19.61 135.72 17.53 674.25

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×